Edvince is preparing a phase I/II study in patients suffering from subarachnoid haemorrhage (SAH).
The study is an interventional, double-blind, placebo-controlled, multiple-ascending dose first-in-human Phase I/II study in patients with subarachnoid hemorrhage. The primary objective is to investigate the safety and tolerability of the study drug in patients diagnosed with subarachnoid hemorrhage and in need of an intraventricular drain.
The study drug will be administered via the drain directly into the brain. A total of 3 doses will be given to each patient. The first study will be completed in 2023 as a phase I/II to assess safety and efficacy.